COVID 19: WHO Recommends 2 Treatment Drugs
The World Health Organisation (WHO) has recommended 2 new drugs for the treatment of COVID 19 patients
The drugs, baricitinib, and sotrovimab were recommended after seven trials involving over 4,000 patients with COVID
The health body states that evidence shows that the drug improves survival and reduces the need for ventilation
The World Health Organisation (WHO) has recommended two new treatment drugs- baricitinib and sotrovimab for COVID 19 patients.
In a statement that was released on Thursday, the health body disclosed that its recommendation was based on seven trials involving over 4,000 patients, with severe, non-severe, and critical COVID.
Barictinib which is also used to treat rheumatoid arthritis was recommended for patients with severe or critical COVID alongside corticosteroids.
WHO states that the recommendation was made based on evidence showing that it increases the chances of survival reduces the need for ventilation.
The experts noted that baricitinib has similar effects to other arthritis drugs called interleukin-6inhibitors. It is recommended that the most available and affordable is selected and both drugs should not be used at the same time.
There was also a recommendation for the use of a monoclonal antibody, sotrovimab but only in patients with the highest risk of hospitalization.
It is however noted that the effectiveness of this drug against new variants like omicron is uncertain.